SAN DIEGO, March 29 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. , a biopharmaceutical company committed to the discovery, development and commercialization of novel anti-infective medicines, announced that it will be presenting at the Lehman Brothers Eighth Annual Global Healthcare Conference on Wednesday, March 30, 2005, at 4:45 p.m. Eastern Time at the Loews Miami Beach Hotel.
Kleanthis G. Xanthopoulos, Ph.D., Anadys' President and Chief Executive Officer, will present an overview of Anadys, its clinical development and discovery programs and upcoming milestones. A live webcast of the presentation can be accessed at http://www.anadyspharma.com/. The replay will be available approximately one hour after the presentation and will be archived until April 13, 2005.
About Anadys
Anadys Pharmaceuticals, Inc. (http://www.anadyspharma.com/) is a biopharmaceutical company committed to advancing patient care by discovering, developing and commercializing novel small molecule medicines for the treatment of hepatitis C virus (HCV), hepatitis B virus (HBV) and bacterial infections. Anadys' clinical development programs include the oral prodrug ANA975 for the treatment of HCV and HBV, and ANA380 for the treatment of HBV. In addition, Anadys' anti-infective therapeutic platform, including core capabilities in Toll-Like Receptor-based small molecules and structure-based drug design, is designed to advance a strong and continual pipeline of drug candidates into the clinic. Additional information regarding Anadys will be included in the Company's Form 10-K for the year ended December 31, 2004.
Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. In particular, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to successfully develop and market products, difficulties or delays in its clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments involving future products and its ability to obtain additional funding to support its operations. These and other factors that may cause actual results to differ are more fully discussed in the "Risk Factors" section of Anadys' Form 10-K for the year ended December 31, 2004. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
Anadys Pharmaceuticals, Inc.CONTACT: Michael Kamdar, Sr. VP, Corporate Development and Finance,+1-858-530-3667, cc@anadyspharma.com, or Pete De Spain, Manager, CorporateCommunications, +1-858-530-3653, pdespain@anadyspharma.com, both of AnadysPharmaceuticals, Inc.
Web site: http://www.anadyspharma.com/
